Neuroelectrophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Thailand.
Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Thailand.
FEBS J. 2022 Oct;289(20):6435-6455. doi: 10.1111/febs.16474. Epub 2022 May 18.
Doxorubicin (DOX), an effective, extensively used chemotherapeutic drug, can cause cognitive deterioration in cancer patients. The associated debilitating neurological sequelae are referred to as chemobrain. Our recent work demonstrated that Dox treatment resulted in an imbalance in mitochondrial dynamics, ultimately culminating in cognitive decline in rats. Therefore, in this study, we aim to explore the therapeutic efficacy of a pharmacological intervention, which modulates mitochondrial dynamics using a potent mitochondrial fission inhibitor (Mdivi-1) and mitochondrial fusion promoter (M1) against Dox-induced chemobrain. In the study, male Wistar rats were randomly assigned to receive either normal saline solution or six doses of Dox (3 mg·kg ) via intraperitoneal injection. Then, the Dox-treated rats were intraperitoneally given either 1% DMSO as the vehicle, Mdivi-1 (1.2 mg·kg ), M1 (2 mg·kg ), or a combined treatment of Mdivi-1 and M1 for 30 consecutive days. Long-term learning and memory were evaluated using the novel object location task and novel object recognition task. Following euthanasia, the rat brains were dissected to enable further molecular investigation. We demonstrated that long-term treatment with mitochondrial dynamic modulators suppressed mitochondrial fission in the hippocampus following Dox treatment, leading to an improvement in brain homeostasis. Mitochondrial dynamic modulator treatments restored cognitive function in Dox-treated rats by attenuating neuroinflammation, decreasing oxidative stress, preserving synaptic integrity, reducing potential Alzheimer's related lesions, and mitigating both apoptosis and necroptosis following Dox administration. Together, our findings suggested that mitochondrial dynamics modulators protected against Dox-induced cognitive impairment by rebalancing mitochondrial homeostasis and attenuating both oxidative and inflammatory insults.
多柔比星(DOX)是一种有效的、广泛应用的化疗药物,会导致癌症患者认知能力下降。相关的使人衰弱的神经后遗症被称为化疗脑。我们最近的工作表明,DOX 治疗导致线粒体动力学失衡,最终导致大鼠认知能力下降。因此,在这项研究中,我们旨在探索一种药物干预的治疗效果,该干预通过使用一种有效的线粒体分裂抑制剂(Mdivi-1)和线粒体融合促进剂(M1)来调节线粒体动力学,以对抗 DOX 引起的化疗脑。在研究中,雄性 Wistar 大鼠被随机分为接受生理盐水或六次 DOX(3mg·kg )腹腔注射。然后,用 1%DMSO 作为载体、Mdivi-1(1.2mg·kg )、M1(2mg·kg )或 Mdivi-1 和 M1 的联合治疗对 DOX 处理的大鼠进行腹腔内给药,连续 30 天。使用新物体定位任务和新物体识别任务评估长期学习和记忆。安乐死后,分离大鼠大脑进行进一步的分子研究。我们表明,线粒体动力学调节剂的长期治疗抑制了 DOX 处理后海马体中的线粒体分裂,从而改善了大脑的内稳态。线粒体动力学调节剂通过减轻神经炎症、减少氧化应激、维持突触完整性、减少潜在的与阿尔茨海默病相关的病变以及减轻 DOX 给药后的细胞凋亡和坏死来改善 Dox 处理大鼠的认知功能。总之,我们的研究结果表明,线粒体动力学调节剂通过重新平衡线粒体内稳态和减轻氧化和炎症损伤,预防 DOX 引起的认知障碍。